Want to see GB:IMM full AI Analyst Report?
Top Page
ImmuPharma
(LSE:IMM)
Select Model
Select Model
Rating:41Neutral
Price Target:
3.50 p
▼(-22.22% Downside)
Action:Reiterated
Date:05/28/26
The score is primarily constrained by weak financial performance (no revenue, continued losses and cash burn, and a fragile equity position), partially offset by low debt. Technicals add modestly negative pressure due to a weak longer-term trend and bearish MACD, while valuation cannot be meaningfully supported with the provided P/E and missing dividend yield.
Positive Factors
Minimal Debt
Minimal debt limits interest and refinancing pressure, preserving financial flexibility while the company advances its development plans. This is particularly important for a clinical-stage business with uncertain timing of future funding, partnerships, or product revenue.
Negative Factors
No Recent Revenue
The absence of revenue means the company has no demonstrated commercial earnings engine supporting operations. Until a candidate is partnered, approved, or commercialized, funding for research and development will remain dependent on capital markets or other external sources.
Read all positive and negative factors
Positive Factors
Negative Factors
Minimal Debt
Minimal debt limits interest and refinancing pressure, preserving financial flexibility while the company advances its development plans. This is particularly important for a clinical-stage business with uncertain timing of future funding, partnerships, or product revenue.
Read all positive factors
ImmuPharma (IMM) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£27.39M
Dividend YieldN/A
Average Volume (3M)15.00M
Price to Earnings (P/E)―
Beta (1Y)0.89
Revenue GrowthN/A
EPS Growth36.67%
CountryUK
Employees7
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding623,911,400
10 Day Avg. Volume4,827,745
30 Day Avg. Volume14,996,625
Financial Highlights & Ratios
PEG Ratio0.44
Price to Book (P/B)44.28
Price to Sales (P/S)0.00
P/FCF Ratio-12.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
ImmuPharma Business Overview & Revenue Model
Company Description
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics focuses on autoimmunity and inflammation, and anti-infectives therapeutic areas. The company’s lea...
How the Company Makes Money
Revenue model details sufficient to describe how ImmuPharma currently makes money (e.g., recurring product sales, disclosed licensing/royalty income, or specific collaboration payments) are null based on the information available here. As a clinic...
ImmuPharma Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
44
Neutral
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 118.35K |
| Gross Profit | -35.30K | -63.88K | -37.61K | -118.00K | 118.35K |
| EBITDA | -2.51M | -2.61M | -3.02M | -2.91M | -8.70M |
| Net Income | -1.81M | -2.48M | -2.92M | -3.81M | -8.17M |
Balance Sheet | |||||
| Total Assets | 1.88M | 977.01K | 2.72M | 3.97M | 6.00M |
| Cash, Cash Equivalents and Short-Term Investments | 1.35M | 236.90K | 208.48K | 667.81K | 1.65M |
| Total Debt | 0.00 | 0.00 | 0.00 | 111.00 | 700.00 |
| Total Liabilities | 1.19M | 1.52M | 1.67M | 1.45M | 1.58M |
| Stockholders Equity | 686.86K | -542.86K | 1.06M | 2.52M | 4.41M |
Cash Flow | |||||
| Free Cash Flow | -2.37M | -1.77M | -1.36M | -2.45M | -4.88M |
| Operating Cash Flow | -2.37M | -1.77M | -1.36M | -2.35M | -4.83M |
| Investing Cash Flow | 6.91K | 1.29M | 188.76K | -77.42K | -50.28K |
| Financing Cash Flow | 3.43M | 500.02K | 722.10K | 1.55M | 702.05K |
ImmuPharma Technical Analysis
Negative
4.50
Price Trends
4.08
Negative
4.28
Negative
5.76
Negative
Market Momentum
-0.05
Positive
45.86
Neutral
58.69
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:IMM, the sentiment is Negative. The current price of 4.5 is above the 20-day moving average (MA) of 4.07, above the 50-day MA of 4.08, and below the 200-day MA of 5.76, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 45.86 is Neutral, neither overbought nor oversold. The STOCH value of 58.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:IMM.
ImmuPharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | £25.59M | -54.86 | -5.25% | ― | 95.16% | 85.60% | |
53 Neutral | £116.37M | -18.00 | 90.29% | ― | ― | 69.01% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | £64.89M | -9.35 | -55.47% | ― | ― | 19.83% | |
47 Neutral | £36.92M | -7.69 | -284.01% | ― | ― | -105.65% | |
41 Neutral | £27.39M | -10.00 | -353.21% | ― | ― | 36.67% | |
29 Underperform | £41.17M | -2.75 | -2807.75% | ― | ― | -28.29% |
* Healthcare Sector Average
GB:IMM
ImmuPharma
3.62
1.94
115.82%
GB:SAR
Sareum Holdings
29.00
3.00
11.54%
GB:SCLP
Scancell Holdings
9.50
-0.75
-7.32%
GB:HEMO
HemoGenyx Pharmaceuticals Plc
640.00
482.25
305.71%
GB:SBTX
SkinBioTherapeutics
9.50
-5.50
-36.67%
GB:POLB
Poolbeg Pharma Ltd.
8.80
5.80
193.33%
ImmuPharma Corporate Events
Business Operations and StrategyProduct-Related Announcements
ImmuPharma taps Kymos as bioanalytical partner to advance Kapiglucagon diabetes programme
Positive
Aug 10, 2026
ImmuPharma has appointed Kymos Group as the bioanalytical contract research partner for its Kapiglucagon programme, following a competitive tender, marking another key milestone in the drug’s non-clinical and early clinical development. The ...
Business Operations and StrategyProduct-Related Announcements
ImmuPharma Taps Thermo Fisher as CDMO for Kapiglucagon Diabetes Program
Positive
Jul 22, 2026
ImmuPharma has selected Thermo Fisher Scientific’s Patheon pharma services as the contract development and manufacturing organisation for drug product work on its Kapiglucagon program. The appointment follows the earlier choice of Bachem AG ...
Business Operations and StrategyShareholder Meetings
ImmuPharma shareholders back all resolutions at 2026 AGM
Positive
Jun 25, 2026
ImmuPharma reported that all six resolutions at its 2026 annual general meeting were approved by shareholders, including the receipt of 2025 accounts, reappointment of a director and the auditor, and authorisations related to share allotment. Inve...
Business Operations and StrategyProduct-Related Announcements
ImmuPharma taps Bachem to manufacture Kapiglucagon API for Type 1 diabetes program
Positive
Jun 25, 2026
ImmuPharma has selected Swiss-based Bachem AG as its active pharmaceutical ingredient manufacturing partner for Kapiglucagon, marking a key Chemistry, Manufacturing and Controls milestone for the Type 1 diabetes program. The move strengthens the s...
Business Operations and Strategy
ImmuPharma flags early-stage P140 glioblastoma research while reaffirming autoimmune focus
Positive
Jun 24, 2026
ImmuPharma has highlighted early-stage research from the University of Murcia, published in the journal Autophagy, indicating potential applications of its P140 peptide in glioblastoma, an aggressive brain cancer. The company has been following th...
Business Operations and StrategyExecutive/Board Changes
ImmuPharma flags Incanthera board shake-up as chairman steps down
Neutral
Jun 4, 2026
ImmuPharma PLC has highlighted a corporate update from partner company Incanthera plc, noting that Tim McCarthy has stepped down as Executive Chairman of Incanthera as part of wider board changes. The announcement, issued via a non-regulatory comm...
Financial DisclosuresShareholder Meetings
ImmuPharma Sets June AGM as 2025 Annual Report Reaches Shareholders
Neutral
Jun 2, 2026
ImmuPharma PLC has dispatched its Notice of Annual General Meeting and the Annual Report and Accounts for the year ended 31 December 2025 to shareholders, with electronic versions to be made available on the company’s website. The AGM is sch...
Business Operations and StrategyExecutive/Board ChangesFinancial DisclosuresPrivate Placements and Financing
ImmuPharma Narrows Loss, Raises Funds as P140 Autoimmune Platform Advances
Positive
May 27, 2026
ImmuPharma reported a narrowed loss of £1.8m for 2025, stable operating costs and a year-end cash balance of £1.4m, subsequently bolstered by a £6.47m equity raise in April 2026 to support its pipeline. The company advanced its P140...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.